185 related articles for article (PubMed ID: 36996276)
21. Anti-mitochondrial autoantibodies are associated with cardiomyopathy, dysphagia, and features of more severe disease in adult-onset myositis.
Sabbagh SE; Pinal-Fernandez I; Casal-Dominguez M; Albayda J; Paik JJ; Miller FW; Rider LG; Mammen AL; Christopher-Stine L;
Clin Rheumatol; 2021 Oct; 40(10):4095-4100. PubMed ID: 33851273
[TBL] [Abstract][Full Text] [Related]
22. Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study.
Dani L; Holmqvist M; Martínez MA; Trallero-Araguas E; Dastmalchi M; Svensson J; Labrador-Horrillo M; Selva-O'Callaghan A; Lundberg IE
Clin Exp Rheumatol; 2020; 38(1):67-73. PubMed ID: 31365334
[TBL] [Abstract][Full Text] [Related]
23. Cutaneous manifestations of dermatomyositis characterized by myositis-specific autoantibodies.
Okiyama N; Fujimoto M
F1000Res; 2019; 8():. PubMed ID: 31824645
[TBL] [Abstract][Full Text] [Related]
24. Autoantibodies against four-and-a-half-LIM domain 1 (FHL1) in inflammatory myopathies: results from an Australian single-centre cohort.
Galindo-Feria AS; Horuluoglu B; Day J; Fernandes-Cerqueira C; Wigren E; Gräslund S; Proudman S; Lundberg IE; Limaye V
Rheumatology (Oxford); 2022 Oct; 61(10):4145-4154. PubMed ID: 35022656
[TBL] [Abstract][Full Text] [Related]
25. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups.
Love LA; Leff RL; Fraser DD; Targoff IN; Dalakas M; Plotz PH; Miller FW
Medicine (Baltimore); 1991 Nov; 70(6):360-74. PubMed ID: 1659647
[TBL] [Abstract][Full Text] [Related]
26. [Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis].
Gan YZ; Li YH; Zhang LH; Ma L; He WW; Jin YB; An Y; Li ZG; Ye H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):1001-1008. PubMed ID: 33331305
[TBL] [Abstract][Full Text] [Related]
27. Clinical profile of anti-NXP-2 antibody-positive inflammatory myositis and outcome in an Indian population.
Manwatkar A; Padiyar S; Nair A; Jha A; Kumar S; Yadav B; Prakash JAJ; Das JK; Mathew J
Clin Rheumatol; 2023 Dec; 42(12):3289-3297. PubMed ID: 37801141
[TBL] [Abstract][Full Text] [Related]
28. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan.
Iwata N; Nakaseko H; Kohagura T; Yasuoka R; Abe N; Kawabe S; Sugiura S; Muro Y
Mod Rheumatol; 2019 Sep; 29(5):802-807. PubMed ID: 30092736
[No Abstract] [Full Text] [Related]
29. Clinical significance of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis: a monocentric cross-sectional study.
Yang H; Yan T; Zhang X; Sun W; Liu L; Du Y; Xue J
Clin Rheumatol; 2022 Aug; 41(8):2439-2448. PubMed ID: 35422109
[TBL] [Abstract][Full Text] [Related]
30. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis.
Betteridge ZE; Gunawardena H; Chinoy H; North J; Ollier WE; Cooper RG; McHugh NJ;
Ann Rheum Dis; 2009 Oct; 68(10):1621-5. PubMed ID: 18930994
[TBL] [Abstract][Full Text] [Related]
31. Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis.
Gupta L; Naveen R; Gaur P; Agarwal V; Aggarwal R
Semin Arthritis Rheum; 2021 Feb; 51(1):113-120. PubMed ID: 33360322
[TBL] [Abstract][Full Text] [Related]
32. Anti-TIF1-γ antibody and cancer-associated myositis: A clinicohistopathologic study.
Hida A; Yamashita T; Hosono Y; Inoue M; Kaida K; Kadoya M; Miwa Y; Yajima N; Maezawa R; Arai S; Kurasawa K; Ito K; Shimada H; Iwanami T; Sonoo M; Hatanaka Y; Murayama S; Uchibori A; Chiba A; Aizawa H; Momoo T; Nakae Y; Sakurai Y; Shiio Y; Hashida H; Yoshizawa T; Sakiyama Y; Oda A; Inoue K; Takeuchi S; Iwata NK; Date H; Masuda N; Mikata T; Motoyoshi Y; Uesaka Y; Maeda MH; Nakashima R; Tsuji S; Kwak S; Mimori T; Shimizu J
Neurology; 2016 Jul; 87(3):299-308. PubMed ID: 27343066
[TBL] [Abstract][Full Text] [Related]
33. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.
Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Dankó K
Autoimmun Rev; 2014 Dec; 13(12):1211-9. PubMed ID: 25182203
[TBL] [Abstract][Full Text] [Related]
34. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies.
Hausmanowa-Petrusewicz I; Kowalska-Oledzka E; Miller FW; Jarzabek-Chorzelska M; Targoff IN; Blaszczyk-Kostanecka M; Jablonska S
Arthritis Rheum; 1997 Jul; 40(7):1257-66. PubMed ID: 9214426
[TBL] [Abstract][Full Text] [Related]
35. Clinical characteristics of Vietnamese patients with idiopathic inflammatory myopathies and autoantibodies to aminoacyl-transfer RNA synthetases.
Phuong TNT; Ngoc LNT; Rönnelid J; Padyukov L; Lundberg IE
Int J Rheum Dis; 2021 May; 24(5):663-670. PubMed ID: 33788398
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
[TBL] [Abstract][Full Text] [Related]
37. Distinct HLA associations with autoantibody-defined subgroups in idiopathic inflammatory myopathies.
Leclair V; Galindo-Feria AS; Rothwell S; Kryštůfková O; Zargar SS; Mann H; Diederichsen LP; Andersson H; Klein M; Tansley S; Rönnblom L; Lindblad-Toh K; Syvänen AC; Wahren-Herlenius M; Sandling JK; ; McHugh N; Lamb JA; Vencovský J; Chinoy H; Holmqvist M; Bianchi M; Padyukov L; Lundberg IE; Diaz-Gallo LM
EBioMedicine; 2023 Oct; 96():104804. PubMed ID: 37769433
[TBL] [Abstract][Full Text] [Related]
38. Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies: results from a cohort from China.
Wen L; Chen X; Cheng Q; Nie L; Xu J; Yan T; Zhang X; Yang H; Sun W; Liu L; Xue J; Du Y
Clin Rheumatol; 2022 Nov; 41(11):3419-3427. PubMed ID: 35859245
[TBL] [Abstract][Full Text] [Related]
39. [Myositis-specific autoantibodies].
Fujimoto M
Brain Nerve; 2013 Apr; 65(4):449-60. PubMed ID: 23568993
[TBL] [Abstract][Full Text] [Related]
40. Anti-TIF1-γ autoantibodies: warning lights of a tumour autoantigen.
De Vooght J; Vulsteke JB; De Haes P; Bossuyt X; Lories R; De Langhe E
Rheumatology (Oxford); 2020 Mar; 59(3):469-477. PubMed ID: 31883334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
